Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$27.0 million.

  • Zentalis Pharmaceuticals' Cash from Operations rose 3878.31% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$134.0 million, marking a year-over-year increase of 2197.76%. This contributed to the annual value of -$170.9 million for FY2024, which is 1778.54% up from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Cash from Operations stood at -$27.0 million, which was up 3878.31% from -$34.7 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Cash from Operations ranged from a high of -$27.0 million in Q3 2025 and a low of -$79.3 million during Q2 2023
  • For the 4-year period, Zentalis Pharmaceuticals' Cash from Operations averaged around -$42.4 million, with its median value being -$39.7 million (2024).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Cash from Operations tumbled by 8424.48% in 2023 and then soared by 5567.46% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Cash from Operations stood at -$37.3 million in 2022, then dropped by 8.76% to -$40.6 million in 2023, then rose by 2.21% to -$39.7 million in 2024, then surged by 32.09% to -$27.0 million in 2025.
  • Its last three reported values are -$27.0 million in Q3 2025, -$34.7 million for Q2 2025, and -$32.6 million during Q1 2025.